Bli medlem
Bli medlem

Du är här

2015-04-24

Orion Oyj: Orion upgrades full-year outlook for 2015

ORION CORPORATION STOCK EXCHANGE RELEASE 24 APRIL 2015 at 9.25 A.M. EEST

Orion upgrades full-year outlook for 2015
Orion Corporation upgrades the full-year outlook estimate for 2015 provided on
4 February 2015. Operating profit of the first quarter was EUR 83 million
which is 23 % higher than in the previous year. Based on the good start for
the year the company estimates that the full-year operating profit will be
higher than estimated previously.

New full-year outlook estimate for 2015, provided on 24 April 2015

Net sales will be slightly lower than in 2014 (net sales were EUR 1,015
million in 2014).

Operating profit is estimated to exceed EUR 230 million.

The Group's capital expenditure will be about EUR 50 million excluding
substantial corporate or product acquisitions. (The Group's capital
expenditure was EUR 57 million in 2014)

Previous full-year outlook estimate for 2015, provided on 4 February 2015

Net sales will be slightly lower than in 2014 (net sales were EUR 1,015
million in 2014).

Operating profit is estimated to exceed EUR 200 million.

The Group's capital expenditure will be about EUR 50 million excluding
substantial corporate or product acquisitions. (The Group's capital
expenditure was EUR 57 million in 2014)

Orion will publish the Interim Report January-March 2015 on Wednesday, 29
April 2015.

Orion Corporation

-------------------------------------------------
| Timo Lappalainen Olli Huotari |
|President and CEO |
| SVP, Corporate Functions |
-------------------------------------------------
Contact person:

Jari Karlson, CFO
tel. +358 10 426 2883

Publisher:

Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage:www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are central nervous system (CNS) disorders, oncology and respiratory for
which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

HUG#1914392

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.